Lexicon Pharmaceuticals, Inc. (LXRX) is scheduled to report topline results from its Phase 2b PROGRESS study evaluating Pilavapadin or LX9211, an oral, non-opioid investigational inhibitor, in adults with moderate to severe diabetic peripheral neuropathic pain, today at 8:00 a.m.
The PROGRESS study, which commenced in December 2023, has enrolled 496 patients with diabetes and DPNP. The primary endpoint is the change from baseline to Week 8 in the Average Daily Pain Score or ADPS compared to a placebo. Secondary endpoints include burning pain and pain interference with sleep. The study design allowed patients to continue their current DPNP therapy, reflecting real-world use.
Pilavapadin, a small molecule inhibitor of AAK1, demonstrated potential in preclinical studies by reducing neuropathic pain without affecting opioid pathways, according to the company.
Lexicon believes Pilavapadin could be a breakthrough treatment for neuropathic pain, offering a novel approach without the side effects associated with opioids.
LXRX closed Friday's (Feb.28 2025) trading at $0.70 up by 5.73 percent. In premarket trading Monday, the stock is up by 12.40 percent at $0.79 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.